Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
LOL! That's a winning strategy
That last 719k trade is symptomatic of the current situation. Its was someone who bought and held for an hour, then sold at a loss!
NT for anything above 700k now.
Someone wants this on the cheap. Don't let them steal it!
No longer quoted for 2m. Can sell 1.5m for 2.45p though.
Looks like they are trying to cool it down and don't want to pay too much.
Sticky fingers will lead to better prices
Mars, I actually do believe that it is entirely possible that the thought would have crossed their mind. They may also want further patents developed in the future which would lead to more royalties being paid.
Kelly Ventures is listed on the TSX in Canada so don't they have a Canadian shell, if they need one?
Maybe the big seller just now bailed maybe the new broker lined up some serious money.
I withdraw that idea they would not need a Canadian shell and the law over here is too restricted
I know this is off the wall but Ebers was raising £50m if they have succeeded it would be cheaper than paying 25% royalties in a booming cannabinoid market.
2m sell now quoted at just over 2.3p.
Looks like they have exhausted the lower priced sellers and bid is moving up to flush out the next level
I've just run a test quote to sell 2m shares, I was instantly offered 2.25p
Someone wants these.
Something happening and law of averages says it's good for us going forward so I've had 1 very last top up at 2.33.
Said it before and was wrong but surely NFX has bottomed here
I can only imagine that the price is static because there is parity between buying and selling.
I find it hard to believe that the MM's are soaking these up unless they have a buyer in the background.
A lot of questions to answer here with all these trades, can be cleared up with TR1's but only for the largest holders.
Myles still very quiet so I take it he's offloaded, can't understand his silence otherwise
How is this price staying at 2.30ish?
Now on lse trade list 3m+ 21.47 what is going on?
Some large sells have just appeared on ADVFN plus a strange one for over 3m timed at 21:47 last night which also shows here. ADVFN volume this morning now showing at 11m.
What is going on?
Looks to be a transfer of stock on the open market as SP isn't doing much, we've never had trades like it before, I don't remember anything similar after last placing.
I doubt NFX would have paid for that article. Blogs need a constant churn of articles to keep page views up and advertising revenue coming in. They'd welcome as much content as they could publish and I suspect, from the depth and tone of the article, that NFX may have had a hand in writing it and asked proactive 'Would you like to publish this?' in a mutually beneficial relationship. Which again is a sign of the company caring about shareholder value and acting in a much more professional and proactive manner since Anne took over.
As to the big trades..? I'm mystified. I guess we'll have to wait and see a bit longer to find out.
Interesting that Proactive article turned up now with some new soundbites off Anne.
Crossed fingers we start having some TR1's so us little pi's know what the hell is going on with these huge trades.
That's over a fifth of the company's shares traded in two weeks then, well above the 78m added during the placing. Not a single TR1 issued. Is it safe to say that most of our new broker-sourced 'investors' are out already? Where is the twitter coverage that was so highly anticipated from some of those amongst them?
Maybe that's why the company has turned back to Proactive as a mouthpiece, hoping for stickier fingers amongst the smaller retailers?
Will be interesting to see what happens once the volume drops. We’ve seen over 125m shares traded over the last two weeks and the sp is lower than it was back then.
"That was my first thought when I saw it - why now?"
I'm intrigued by that too Flap. Did they pay for that coverage? Money is fairly tight so why? What extra does it offer over and above the Allenby report?
I'm confused. I just hope the recent high volume activity turns out to be the start of something good rather than more smoke and mirrors followed by a PI shafting.
This appears to be the prior from the RNS “ Before moving to Advent, Anne was a Board member and Managing Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals (part of Johnson & Johnson, Inc), where she was responsible for leadership and operations of the company, including discovery / development programmes spanning three novel classes of drug for idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and asthma. Is Johnson & Johnson still interested in IPF.
Anne from the Proactive article “ I know about having worked on an asset for IPF in one of my prior companies. I could see it was a great opportunity.” We know there are only 2 IPF drugs out there so is her prior company still looking?
Don’t know what.